Advertisement

Topics

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

13:49 EDT 11 Aug 2017 | SCRIP

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence...

      

Related Stories

 

Original Article: Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...